ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2910

Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials

Liana Fraenkel1, W. Benjamin Nowell2, Carole Wiedmeyer2, Zhenglin Wei3, Kaleb Michaud4, Tuhina Neogi5, Christine Ramsey1 and David Broniatowski3, 1Yale University School of Medicine, New Haven, CT, 2Global Healthy Living Foundation, Upper Nyack, NY, 3George Washington University, Washington, DC, 4Rheumatology, University of Nebraska Medical Center, Omaha, NE, 5Clinical Epidemiology Research and Training Unit, Boston University School of Medicine, Boston, MA

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: patient outcomes, randomized trials and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Wednesday, October 24, 2018

Session Title: 6W007 ACR Abstract: Patient Outcomes, Preferences, & Attitudes II: PROs (2910–2915)

Session Type: ACR Concurrent Abstract Session

Session Time: 9:00AM-10:30AM

Background/Purpose: Randomized controlled trials currently report benefits and adverse events (AEs) separately, and therefore do not permit comparisons of patients’ overall experiences on one treatment versus another. The purpose of this study is to develop a Global Patient-Reported Outcome Measure (G-PROM) to quantify and compare the distribution of patients’ overall experiences on medications.

Methods: We invited rheumatoid arthritis (RA) patients who were part of an online community to complete a survey, based on Trajectory Mapping (TM) to generate a hierarchy of AEs. The TM survey establishes a hierarchy by enabling patients to indicate whether an AE is worse, better, or no better or worse than a referent AE. TM allows the construction of “equivalence classes” i.e., groups of AEs judged by patients as having a comparable impact on quality of life. We subsequently conducted a second survey in which participants (who did not participate in the initial TM survey) were asked to indicate their preference for pairs of outcomes, where each outcome include both a specified level of benefit [little or no improvement (ACR20 or less), some improvement (between ACR20 and 50), and major improvement (ACR50 and greater)] and an AE (see Figure 1).

Results: 195 participants completed the initial TM survey. The mean age was 53.5 (11.6), 89% were female, and 56% were college graduates. The initial TM survey generated 11 hierarchies of AEs. The final hierarchy (9 levels of AEs ranging from no AEs to serious AEs resulting in irreversible harm) was chosen based on goodness of fit parameters (see Figure 2). 426 participants with similar demographic characteristics completed the second survey. Ratings revealed that when paired with benefits, AEs clustered into 3 main groups: no, mild or manageable AEs (Levels 1-4), moderate AEs (Levels 5-6), and serious AEs (Levels 7-9). Participants’ ratings generated a 5-level hierarchy of global outcomes illustrated in Figure 3.

Conclusion: After validation, G-PROM will enable randomized controlled trials to report the percentage of patients classified into each level; thus, providing patients and their rheumatologists with a much clearer understanding of the range and likelihood of the total effects of competing treatment options on their quality of life.



Disclosure: L. Fraenkel, None; W. B. Nowell, GlaxoSmithKline, 1,Merck & Co., 1,Pfizer, Inc., 1, 2,AbbVie Inc., 1,Bristol-Myers Squibb, 1, 2,Eli Lilly and Co., 1, 2,Janssen, 1,Novartis, 2; C. Wiedmeyer, None; Z. Wei, None; K. Michaud, None; T. Neogi, None; C. Ramsey, None; D. Broniatowski, None.

To cite this abstract in AMA style:

Fraenkel L, Nowell WB, Wiedmeyer C, Wei Z, Michaud K, Neogi T, Ramsey C, Broniatowski D. Development of a Rheumatoid Arthritis Global Outcome Measure to Enable Comparisons of Patient Experiences across Treatment Arms in Randomized Clinical Trials [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 10). https://acrabstracts.org/abstract/development-of-a-rheumatoid-arthritis-global-outcome-measure-to-enable-comparisons-of-patient-experiences-across-treatment-arms-in-randomized-clinical-trials/. Accessed January 18, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/development-of-a-rheumatoid-arthritis-global-outcome-measure-to-enable-comparisons-of-patient-experiences-across-treatment-arms-in-randomized-clinical-trials/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.